Literature DB >> 19833214

Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study.

Christian Windischberger1, Rupert Lanzenberger, Alexander Holik, Christoph Spindelegger, Patrycja Stein, Ulrike Moser, Florian Gerstl, Martin Fink, Ewald Moser, Siegfried Kasper.   

Abstract

Area-specific and stimulation-dependent changes of human brain activation by selective serotonin reuptake inhibitors (SSRI) are an important issue for improved understanding of treatment mechanisms, given the frequent prescription of these drugs in depression and anxiety disorders. The aim of this neuroimaging study was to investigate differences in BOLD-signal caused by administration of the SSRIs escitalopram and citalopram using pharmacological functional magnetic resonance imaging (pharmaco-fMRI). Eighteen healthy subjects participated in a placebo-controlled, randomized, double-blind study in cross-over repeated measures design. Each volunteer performed facial emotional discrimination and a sensorimotor control paradigm during three scanning sessions. Citalopram (20 mg/d), escitalopram (10 mg/d) and placebo were administered for 10 days each with a drug-free period of at least 21 days. Significant pharmacological effects on BOLD-signal were found in the amygdala, medial frontal gyrus, parahippocampal, fusiform and middle temporal gyri. Post-hoc t-tests revealed decreased BOLD-signal in the right amygdala and left parahippocampal gyrus in both pharmacological conditions, compared to placebo. Escitalopram, compared to citalopram, induced a decrease of BOLD-signal in the medial frontal gyrus and an increase in the right fusiform and left parahippocampal gyri. Drug effects were concentrated in brain regions with dense serotonergic projections. Both escitalopram and citalopram attenuated BOLD-signal in the amygdala and parahippocampal cortex to emotionally significant stimuli compared to control stimuli. We believe that reduced reactivity in the medial frontal gyrus found for escitalopram compared to citalopram administration might explain the response differences between study drugs as demonstrated in previous clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833214     DOI: 10.1016/j.neuroimage.2009.10.013

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  42 in total

Review 1.  Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches.

Authors:  Mary L Phillips; Henry W Chase; Yvette I Sheline; Amit Etkin; Jorge R C Almeida; Thilo Deckersbach; Madhukar H Trivedi
Journal:  Am J Psychiatry       Date:  2015-02-01       Impact factor: 18.112

2.  Pregabalin influences insula and amygdala activation during anticipation of emotional images.

Authors:  Robin L Aupperle; Lakshmi Ravindran; Dharol Tankersley; Taru Flagan; Nathan R Stein; Alan N Simmons; Murray B Stein; Martin P Paulus
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

3.  Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge.

Authors:  Daniel H Wolf; Theodore D Satterthwaite; James Loughead; Amy Pinkham; Eve Overton; Mark A Elliott; Gersham W Dent; Mark A Smith; Ruben C Gur; Raquel E Gur
Journal:  Psychopharmacology (Berl)       Date:  2011-05-21       Impact factor: 4.530

Review 4.  Dispositional negativity: An integrative psychological and neurobiological perspective.

Authors:  Alexander J Shackman; Do P M Tromp; Melissa D Stockbridge; Claire M Kaplan; Rachael M Tillman; Andrew S Fox
Journal:  Psychol Bull       Date:  2016-10-10       Impact factor: 17.737

5.  Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex.

Authors:  Paul G Unschuld; Suresh E Joel; James J Pekar; Sarah A Reading; Kenichi Oishi; Julie McEntee; Megan Shanahan; Arnold Bakker; Russell L Margolis; Susan S Bassett; Adam Rosenblatt; Susumu Mori; Peter C van Zijl; Christopher A Ross; Graham W Redgrave
Journal:  Psychiatry Res       Date:  2012-09-11       Impact factor: 3.222

6.  Effects of Escitalopram Administration on Face Processing in Intermittent Explosive Disorder: An fMRI Study.

Authors:  Henk Cremers; Royce Lee; Sarah Keedy; K Luan Phan; Emil Coccaro
Journal:  Neuropsychopharmacology       Date:  2015-06-24       Impact factor: 7.853

Review 7.  'It's the way that you look at it'--a cognitive neuropsychological account of SSRI action in depression.

Authors:  Catherine J Harmer; Philip J Cowen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

Review 8.  Identifying serotonergic mechanisms underlying the corticolimbic response to threat in humans.

Authors:  Patrick M Fisher; Ahmad R Hariri
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

9.  Auditory processing in remitted major depression: a long-term follow-up investigation using 3T-fMRI.

Authors:  Peter Zwanzger; M Zavorotnyy; J Diemer; T Ruland; K Domschke; M Christ; N Michael; B Pfleiderer
Journal:  J Neural Transm (Vienna)       Date:  2012-08-25       Impact factor: 3.575

10.  Altered emotion processing circuits during the anticipation of emotional stimuli in women with borderline personality disorder.

Authors:  Sigrid Scherpiet; Annette B Brühl; Sarah Opialla; Lilian Roth; Lutz Jäncke; Uwe Herwig
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-08       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.